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 The study of metabolism is fundamental to understanding the basis of 
disease. Subtle differences in metabolites, and shunting of molecules from 
one pathway to another can have profound effects on cellular physiology. In 
the case of cancer cells this metabolic balance is often severely disrupted. 
Many cancer cells rapidly consume glucose to produce pyruvate, but rather 
than entering the mitochondria for oxidation, it is reduced to lactate and 
excreted from the cell. This phenomenon is known as the “Warburg effect” 
and provides the cell ample biosynthetic precursors for proliferation, many of 
which are side-reactions of glycolysis. 
 Similar to cancer cells, stem cells also place a heavy metabolic 
emphasis on glycolysis.  During the process of differentiation, however, stem 
cells shift their metabolic profile towards oxidative phosphorylation and 
mitochondrial respiration. Unlike stem cells, many cancer cells are limited in 
their ability to adapt to a different, more oxidative metabolic regime.  
 In both cancer cells and stem cells, the fate of pyruvate is tightly 
controlled. The mitochondrial pyruvate carrier (MPC), a heterodimeric 
protein complex, is required for pyruvate import into the mitochondria. The 
recent discovery of the genes encoding the MPC have provided a new lens to 
 evaluate pyruvate metabolism in normal and disease physiology. Herein, the 
role of the MPC and its connection to the Warburg effect are described in the 
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The cure of human cancer will be the resultant of biochemistry of cancer  
and of biochemistry of man. 
 
Dr. Otto Warburg 
Meeting of the Nobel Laureates, Lindau, Germany 
June 30, 1966 
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1.1 An Historic Perspective 
Any thesis on cancer metabolism would be remiss if not to discuss the 
pioneering work of Dr. Otto Warburg. In the 1920s, Dr. Warburg observed 
that tissue homogenized from a rat liver tumors respired differently than 
that of a normal rat liver. The studies were simple and elegant in their 
construction and quantified the consumption of glucose in a buffered solution, 
and its conversion to carbon dioxide versus its excretion from the cell as 
lactate. Dr. Warburg attributed this difference in cellular metabolism to be 
due to defective respiratory enzymes within the cancer cells. He received the 
Nobel Prize in Physiology for this discovery in 1931.1 
However, Dr. Warburg’s theory was dismissed when mitochondria 
isolated from cancer cells were shown to still contain machinery which would 
actively respire, and the ‘Warburg effect’ fell out of vogue for many years. 
Still, Dr. Warburg continued his research on cancer metabolism and cellular 
respiration. 
 Four years before his death, at the 1966 meeting of Nobel Laureates in 
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Lindau, Germany, Dr. Warburg presented another discovery, where he 
showed that hypoxia was sufficient to irreversibly drive a change from 
“normal” embryonic metabolism to cancer metabolism: 
If one puts embryonic mouse cells into a suitable culture medium 
saturated with physiological oxygen pressures, they will grow outside 
the mouse body, in vitro, and indeed as pure aerobes, with a pure 
oxygen respiration, without a trace of fermentation. However, if during 
the growth one provides an oxygen pressure so reduced that the oxygen 
respiration is partially inhibited, the purely aerobic metabolism of the 
mouse embryonic cells is quantitatively altered within 48 h, in the 
course of two cell divisions, into the metabolism characteristic of 
fermenting cancer cells.  
 
If one then brings such cells, in which during their growth under 
reduced oxygen pressure a cancer cell metabolism has been produced, 
back under the original high oxygen pressure, and allows the cell to 
grow further, the cancer metabolism remains. The transformation of 
embryonic cell metabolism into cancer cell metabolism can thus be 
irreversible, an important result, since the origin of cancer cells from 
normal body cells is an irreversible process.2 
 
 In effect, Dr. Warburg’s lecture was the first mention of the concept of 
“metabolic inflexibility” of cancer cells, a hypothesis that is central to both 




(1) Nobel Lectures, Physiology or Medicine 1922-1941; Elsevier Publishing 
Company: Amsterdam, 1965. 
 
(2) Warburg, O.; The Prime Cause and Prevention of Cancer. Presented at 
the Lindau Meeting of the Nobel Laureates, Lindau, Germany, 1966. 
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IN VIVO STUDY OF THE MPC IN MOUSE COLON EPITHELIUM 
 
4.1 Abstract 
 Deregulated cellular energetics is now firmly established as a 
hallmark of cancer,1 and much work is being done to dissect the mechanisms 
enforcing aerobic glycolysis, or the Warburg effect. Similar to glycolytic 
cancer cells, many stem cells limit mitochondrial oxidation of carbons in favor 
of glycolysis. Within the colon, crypt stem cells have been shown to be the cell 
of origin for many colon adenocarcinomas. The mitochondrial pyruvate 
carrier (MPC) is sufficient to repress the Warburg effect in colon cancer cells 
in vitro, and its expression decreases tumor growth, owing to the metabolic 
inflexibility of this type of cancer. Here we investigate whether forcing the 
Warburg effect, via deletion of the MPC in colon stem cells, metabolically 
“primes” cells for transformation, or promotes stemness by limiting the 
mitochondrial oxidation necessary for differentiation. 
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4.2 Introduction 
The metabolic derangements of cancer were first examined nearly a 
century ago, when it was observed that cancers perform glycolysis 
irrespective of oxygen tension, and at the expense of complete mitochondrial 
oxidation of carbon sources.2 This phenomenon is known as the “Warburg 
effect.” Over the past two decades, there has been resurgence of research on 
cancer metabolism,3-5 with the hope that understanding the metabolic 
phenotype of cancer can lead do the development of novel 
chemotherapeutics.6-10 
 Central to the “Warburg effect” is the fate of pyruvate; whether it is 
transported into the mitochondrion for further oxidation or reduced to lactate 
and excreted from the cell.11 Each of the proteins surrounding pyruvate have 
been shown to be deregulated in some fashion or another in cancer, including 
pyruvate kinase,12-17 lactate dehydrogenase,18-23 and pyruvate dehydrogenase 
kinase (PDK),24-26 as well as the mitochondrial pyruvate carrier (MPC).27 The 
extent of regulation of pyruvate formation and destruction in normal and 
disease physiology underlines the importance of this three carbon molecule. 
 Proliferative cells, including stem cells, exhibit a similar metabolic 
paradigm as the “Warburg effect,” where mitochondrial oxidation is reduced 
in favor of increased glycolysis.28-31 Stem cells, much like cancer cells, have an 
increased requirement for biosynthetic building blocks32,33 for the 
construction of nucleotides, lipids, and amino acids, many of which are 
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intermediates of glycolysis.3,33,34 During the process of differentiation, stem 
cells generally undergo a shift from glycolytic to more mitochondrial carbon 
oxidation, owing to an increased energetic demand of the differentiated 
tissue.35,36 
 Previous work in colon cancer showed that reexpression of the 
mitochondrial pyruvate carrier was sufficient to repress the “Warburg effect” 
and decrease xenograft tumor growth.37 These deleterious effects manifest in 
the “stem cell like” or cancer stem cell compartment, suggesting that the 
MPC may also play an important role in the metabolism, maintenance, 
and/or differentiation of stem cells.  
 Several questions remained after the Molecular Cell paper in 2014 
regarding the connection between the MPC, stem cells, and cancer.37 Is the 
MPC required for differentiation, or conversely is its absence required for the 
maintenance of stemness? Is MPC1 a tumor suppressor gene? In sum, these 
questions address whether metabolism itself is simply a bystander, 
responding passively to cellular energetic needs, or whether modulation of 
metabolism, and metabolism alone is sufficient to drive proliferation and 
tumorigenesis. This chapter highlights some preliminary data towards 
answering these fundamental questions. 
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4.3 Results 
4.3.1 Generation of Colon Stem Cell MPC1  
Conditional Knockout Mouse 
This study begins by obtaining a transgenic mouse harboring an 
Mpc1tm1a(EUCOMM)Wtsi targeted allele from the Wellcome Trust Sanger Institute 
(Figure 4.1). Mice were crossed with germline FLP-Cre mice to remove the 
reporter and selection cassette. Homozygous Mpc1 and Mpc2 knockout mice 
are embryonic lethal,38 so the conditional allele was validated by generating 
MEF lines from a heterozygous Mpc1flox/wt cross. After transient transfection 
with GFPCre,39 recombination and loss of MPC1 was validated by western 
blot (Figure 4.2). The loss of MPC2 protein is consistent with previous 
studies40-42 that have shown knockdown of either Mpc1 or Mpc2 is sufficient 
to lose the complex in mitochondria. 
Stem cells reside in the base of the colon crypt, and are generally 
stratified into a rapid-cycling (Lgr5)43,44 or slow-cycling/quiescent (Lrig1)45 
component (Figure 4.3A). Previous work identified Lrig1 stem cells within 
the colon crypt as a cell-of-origin for colon adenocarcinoma.46 To assess the 
role of the MPC in maintaining stemness and/or its potential function as a 
tumor suppressor, we crossed Mpc1flox mice with Lrig1CreERT2 mice (Figure 
4.3B). Mice were harvested 30 days after tamoxifen injection and Swiss-
rolled, fixed, and sectioned colons were analyzed by IHC.  
Turnover of the colon epithelium occurs approximately every 4-5  
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Figure 4.1 Mpc1 Knockout Mouse Generation. Allele diagrams of targeted 
Mpc1 transgenic and generation of Mpc1 knockout mouse. Cross with Flp 
recombinase removed the reporter and selection cassette. Cre-mediated 
recombination removes exons 3-5. 
  
	   58 
 
 
Figure 4.2 MPC1 Knockout Validation. A) Transient transfection of 
MPC1flox/flox MEFs with plasmids encoding GFP or GFPCre (note cytoplasmic 
versus nuclear localization). B) Western blot of FACS sorted GFP positive 
cells. Note loss of MPC1 and MPC2 protein in GFPCre positive cells. 
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Figure 4.3 Validation of Mpc1 Colon Stem Cell Knockout.  A) Schematic 
diagram of the colon crypt. From bottom to top: rapid-cycling Lgr5+ crypt 
base columnar cells (CBCC) at the bottom, slow-cycling Lrig1+ “+4 cells,” 
transient amplifying (TA) cells and differentiated cells. During 
differentiation, crypt cells transition from glycolytic to OXPHOS as they 
move up the crypt. B) Diagram of transgenic Lrig1tm1.1(Cre/ERT2)Rjc/J allele. 
CreERT2 transcript begins at the endogenous start site for Lrig1. C) 
Immunohistochemistry staining of wild-type, heterozygous, and homozygous 
knockout colon sections. Note the loss of dark, punctate MPC1 staining (top) 
in the heterozygous and homozygous floxed animals. VDAC staining 
performed as a positive control for mitochondria. Similar to the schematic in 
A, cells near the crypt base have less MPC1 and VDAC than those further up 
the crypt. Scale bars are 100µm. 
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days,44 and at 30 days we observed a loss of MPC1 staining in the entirety of 
the crypt in Mpc1fl/flLrig1CreERT2 mice (Figure 4.3C). Of interesting note is the 
gradient of MPC1 staining from the bottom to the top of the crypt in Mpc1+/+ 
control mice. The staining pattern is the inverse of that previously reported 
for PDK1 in the colon crypt,47 and is consistent with a metabolic shift from 
glycolysis to OXPHOS as cells differentiate and move up the crypt.  
 
4.3.2 Mpc1 Knockout Promotes Proliferation 
in Colon Stem Cells 
We hypothesized that MPC1 is necessary for the glycolysis to OXPHOS 
transition during differentiation, and sought to assess its impact on the colon 
epithelium over time. After 3 days of IP tamoxifen, we harvested a cohort of 
mice at 30-day intervals out to 120 days, and noted no significant 
morphologic change of the colon epithelium by hematoxylin & eosin (H&E) 
staining (Figure 4.4). Similarly, Mpc1fl/fl mice did not have a decrease in 
weight gain compared to control mice (data not shown), suggesting normal 
physiologic function of the colon epithelium.  
However, when we stained for Ki67, a marker of cell proliferation, we 
observed an increased percentage of Ki67 positive nuclei in the knockout 
versus control crypts (Figure 4.5A), which remained throughout the time-
course (Figure 4.4). We also observed an increase in cells with a higher 
nuclear to cytoplasmic ratio by H&E, suggesting that there may be an 
	   62 
Figure 4.4 Time Course of Mpc1 Knockout Crypts. Homozygous wild type and 
knockout mice were treated with tamoxifen and harvested at 30 day intervals 
post-injection for dissection and analysis by IHC. H&E staining shows no 
epithelial collapse or histologic changes between wild-type and knockout 
animals. Ki67 is increased at 30 days in the MPC1 knockout animals, and 
continues to stay increased throughout the time course. MPC1 knockout mice 
also show an increase in Lrig1 positive staining, suggesting an expansion of 
the stem cell compartment. At 30 days the MPC1 knockout animals lack the 
characteristic dark punctate MPC1 staining pattern, which remains absent 
throughout the time course. Boxes dimensions are 220µm per side. 
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Figure 4.5 Proliferation Is Dose-Dependent and Associated with Decreased 
Differentiation. A quantification of % Ki67+ cells in wild type (n=69), 
heterozygous (n=85), and homozygous (n=73) MPC1 knockout crypts. ****; p 
< 0.0001. B Cytokeratin 20 staining of MPC1 wild type and knockout crypts. 
Boxes are 220µm per side. 
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expansion of the stem cell compartment. Indeed, knockout crypts appear to 
contain more Lrig1 cells than wild type controls. MPC1 staining remains 
absent in the knockout cells through 120 days, suggesting that the Ki67+, 
Lrig1+ cells arise from MPC1 negative, Lrig1+ cells and that the crypts are 
not repopulated by daughter cells from another stem cell compartment. We 
further observe a decrease in cytokeratin 20 (CK20) positive cells (Figure 
4.5), a marker of differentiation, reinforcing the notion that MPC knockout 
causes a hyperplasia of the stem cell compartment. 
 
4.3.3 Does Loss of MPC1 Metabolically Prime  
Cells for Transformation? 
While the lack of dysplasia, adenoma, or adenocarcinoma at 120 days 
suggests that Mpc1 itself does not have a tumor suppressor function, 
hyperplasia and hyperproliferation within the colon epithelium is an 
established precursor lesion to colon cancer.48 Previous work showed that 
conditional knockout of one allele of the adenomatous polyposis coli gene 
(Apc1)  in Lrig1 cells results in multiple, fulminant tumors in the distal colon 
within 100 days.46 To test whether Mpc1 knockout metabolically “primes” or 
accelerates cells for transformation, we crossed Mpc1floxLrig1CreERT2 mice with 
mice harboring a floxed Apc allele,49 Apctm1TyJ (Figure 4.6) mice to generate 
the Mpc1floxApcflox/+Lrig1CreERT2  conditional knockout line.  
Similar to the Mpc1floxLrig1CreERT2 mice, we injected with tamoxifen 
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Figure 4.6 Diagram of Apc Conditional Knockout Allele. Conditional Apc 
knockout allele obtained from Jackson Laboratories. Upon Cre-mediated 
recombination, all 15 exons of APC (a 90kb genomic region) are deleted.  
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and harvested a cohort of mice at 30-day intervals out to 120 days. To our 
surprise, none of the wild type nor the Mpc1 knockout mice carrying the 
Apcflox allele had obvious tumors on gross dissection anywhere in the GI tract, 
as had previously been reported in the literature. Analysis of IHC sections 
showed loss of MPC1 in the Mpc1fl/fl mice, suggesting functional 
recombination machinery was still intact. APC promotes the degradation of  
beta-catenin,50 and we expect an increase in beta-catenin staining in the 
Apcflox/+ mice. However, there was no change in beta-catenin staining 
patterns or intensity between Apc+/+ and Apcflox/+ mice across the time-course 
(data not shown). In combination with the lack of tumors, dysplasia, and 
normal colon histology, we suspected that the Apcflox allele was simply not 
recombining. 
To determine if the floxed Apc allele is able recombine in vivo, crypts 
were isolated from tamoxifen treated Mpc1flox/+Apcflox/+ mice. We genotyped 
DNA isolated from the colon crypts and confirmed that while the floxed Apc 
allele was present, there was no indication of recombination (Figure 4.7). In 
sum, these data confirmed our suspicion that this Apcflox allele is non-
functional in our system, and data remain inconclusive as to whether Mpc1 
loss promotes or accelerates tumor formation. 
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Figure 4.7 Floxed Apc Allele Does Not Recombine In Vivo. PCR genotyping of 
DNA from isolated crypts from tamoxifen treated MPCflox/+APCflox/+Lrig1Cre-
ERT2 mouse. Genotyping primers used to detect the presence of the floxed 
allele show the anticipated wild-type (340bp) and floxed (471bp) bands. A 





 Previous work over the past several decades have established the 
connection between cancer and metabolic perturbations. Our current and 
previous work focuses on the mechanisms enforcing aerobic glycolysis, and 
means to exploit the metabolic inflexibility of this restrictive paradigm.11 
Similar to glycolytic cancers, many stem cells also reduce mitochondrial 
oxidation in favor of glycolysis. In many cases, the machinery regulating the 
metabolism of both cancers and stem cells is similar, if not the same.29,51-53 
The recent discovery of the genes encoding the MPC,54,55 and its 
connection to the Warburg effect37 is yet another chapter in this continuing 
series. Mpc1 resides at the distal end of chromosome 6, the most frequently 
lost genomic region across all cancers.37,56 The mechanism behind the 
frequency of this genomic loss is not known, however data suggest that 
deletions in the Mpc1 locus occur very early in the development of 
preneoplastic lesions.57,58 
 With the frequent and early loss of Mpc1, and its function as a 
metabolic “gatekeeper” between cytosolic and mitochondrial pyruvate 
metabolism, we inquired whether genomic deletion of Mpc1, and concomitant 
induction of the Warburg effect, can be a precipitating event in oncogenesis. 
In essence, is metabolism a passive bystander, affected by and responding to 
cellular energetic demands, or can a fixed metabolic program determine cell 




 Similarly, it is well appreciated that the stem cells within the colon 
crypt accumulate mutations and serve as the cell of origin for most colon 
cancers.48 Colon crypt stem cells, during the process of differentiation, switch 
from glycolytic to oxidative metabolism, and we hypothesize that the MPC 
may play an important role in differentiation as well. 
 To address both hypotheses, we generated an in vivo model of MPC 
loss in colon crypt stem cells.  Initially, we suspected that deleting Mpc1 in 
the colon stem cells would result in epithelial collapse, as the stem cells 
would fail to differentiate to their more oxidative daughter cells. However, 
throughout our 120-day time course we did not observe any collapsed 
epithelium nor the associated physiologic changes such as weight loss in our 
knockout mice. We also did not observe dysplasia, adenoma, or 
adenocarcinoma over the time course, suggesting that the MPC does not 
function as a tumor suppressor, at least in the canonical sense. 
 We did, however, observe a surprising dose-dependent increase in Ki67 
positivity in Mpc1 knockouts as early as 30 days, which remained throughout 
the time course. If Mpc1 is necessary for differentiation, perhaps loss of Mpc1 
in the stem cell compartment causes an accumulation of progenitor cells 
within the colon.  While the precise identity of these cells is still to be 
determined, IHC staining for stem cell markers and an increased number of 
cells with a low nuclear to cytoplasmic ratio suggests that the Ki67+ cells 




 An expansion of the stem cell compartment, and an increase in 
proliferative cells is an important observation. Canonically, 
hyperproliferation within the colon crypt is one of the earliest identifiable 
lesions in the classical adenoma-carcinoma sequence. Given the stochastic 
model of DNA mutation and the Knudson hypothesis,59 this logically makes 
sense. A dividing cell simply has more opportunities to accumulate mutations 
than a quiescent cell, and an increased number of dividing cells per crypt 
may further enhance the rate of transformation. 
 To assess whether MPC1 loss, and concomitant hyperproliferation and 
expansion of the stem cell compartment increases the rate of tumor 
formation, we chose to use an APC loss-of-heterozygosity model. The 
Lrig1CreERT2Apcflox/+ model previously has been shown to have multiple large 
tumors in the distal colon by 100 days.46  
 Unfortunately, by 120 days we did not observe any tumors on gross 
dissection, nor any dysplasia or microadenomas by histology. Genomic PCR 
analysis of isolated crypts from tamoxifen treated Apcflox/+ mice detected the 
presence of floxed and wild-type alleles, but not a recombined allele.  
 The previous literature which showed tumor formation in an 
Lrig1CreERT2Apcflox mouse utilized an Apc allele with loxP sites flanking only 
exon 14 (Apce14), whereas the APC allele used in this study (Apctm1TyJ) 
possesses loxP sites flanking all 15 Apc exons, a distance of 90kb. A paper 




shared similar pathology when crossed with a germ-line Cre mouse.49 Upon 
further review of the literature, there is a conspicuous absence of publications 
utilizing this specific APCtm1TyJ floxed allele, and no studies published using 
this allele in a CreERT2 driven system.  
 While the data from our APC study are inconclusive, the logic still 
applies that metabolically forcing a “Warburg” program, via knockout of 
MPC1, may still “prime” the cell for transformation. Ultimately this study 
must be repeated, either using the APC floxed allele at exon 14, or another 
mutagenic system such as azoxymethane/dextran sulfate sodium (AOM-DSS) 
treatment.60 The latter may be the more favorable option, as it would directly 
test whether the hyperproliferative stem cell compartment (induced by Mpc1 
deletion) is more susceptible to accumulating DNA damage (by AOM 
treatment) and progressing to adenoma/adenocarcinoma than wild-type, 
metabolically flexible tissue. Furthermore, it would avoid confounding results 




4.5.1 Mouse Breeding and Animal Husbandry  
All mouse work conducted herein was approved and monitored by the 
University of Utah Institutional Animal Care and Use Committee, protocol 




Wellcome Trust Sanger Institute. Microinjection into blastocysts was 
performed by the University of Utah Transgenic and Gene Targeting Core. 
Germ-line Flp mice were obtained from the University of Utah Transgenic 
and Gene Targeting Core. Apc flox (Apctm1TyJ, strain #009045) and Lrig1-
CreERT2 (Lrig1tm1.1(Cre/ERT2)Rjc, strain # 018418) mice were obtained from The 
Jackson Laboratory. Experimental cohorts for Mpc1floxLrig1CreERT2 mice were 
generated by crossing Mpc1flox/flox mice with Lrig1CreERT2/+ mice. 
Mpc1flox/+Lrig1CreERT2/+ mice were then crossed with Mpc1flox/+ mice to generate 
the Mpc1 allelic series experimental cohort. Mpc1floxApcfloxLrig1CreERT2 mice 
were generated by crossing Mpc1flox/flox mice with Apcflox/flox mice. The 
resulting Mpc1flox/+Apcflox/+pups were crossed with Mpc1flox/+Lrig1CreERT2/+ to 
generate the experimental cohort. Recommended genotyping protocols for 
Apc and Lrig1 were followed from the JAX website. Mpc1 genotyping was 
performed as previously described.40 
 
4.5.2 Tissue Harvest and Swiss roll 
Experimental animals were injected intraperitoneally with 100µL 
20mg/mL tamoxifen for 3 days at 8 weeks of age, and sacrificed at either 30, 
60, 90, 120, 150, or 180 days after injection. Mice were fasted for 24h prior to 
sacrifice under isoflurane anesthesia by cervical dislocation and bilateral 
thoracotomy. The lungs, liver, and kidneys were rinsed with PBS, 




mesentery/pancreas were dissected from the small and large intestine, rinsed 
with cold PBS, and fixed in 10% buffered formalin for 48 h.  
The intestines were prepared for Swiss roll61 by removing from the 
abdomen by cutting at the pylorus and the rectum. Small and large intestines 
were separated by cutting at the iliocecal valve. Small and large intestines 
were split open using ball-tip artery scissors, moving from proximal to distal. 
Opened intestinal sections were then rinsed thoroughly in PBS to remove 
feces, and length and weight were measured. Intestines were briefly 
submerged in 10% buffered formalin prior to pinning the distal end to moist 
cork board, lumen side down. Approximately 10cm intestinal segments were 
wound around a pipette tip, moving proximal to distal (proximal intestine 
inside center of Swiss roll). Rolls were carefully placed inside a cassette and 
fixed in 10% buffered formalin for 48 h. After 48 h, all tissues were 
transferred to 70% ethanol. Paraffin embedding and sectioning, and H&E  
staining was performed by the Huntsman Cancer Institute Research 
Histology core. All tissues from each mouse were sectioned and H&E stained. 
 
4.5.3 Immunohistochemistry 
 Colon and small intestine Swiss roll sections from each mouse were 
stained for MPC1, Ki67, beta-catenin, Lrig1, VDAC, CK20, and CD44. IHC 
staining was performed by ARUP Research Histology, using the following 




slides air dry.  Melt slides in a 60°C oven for 30 min. Place slides on 
automated stainer (Ventana Medical Systems). De-paraffin slides with EZ 
Prep solution (Ventana Medical Systems). Pretreat slides with CC1 (Cell 
Conditioning 1, pH 8.5) for 4 min at 95°C (VDAC1), or for 32 min 95°C (Ki-67) 
or 60 min at 95°C (CK20, Beta-catenin, MPC1) or digest with Protease 3 
(Ventana Medical Systems) for 36 min at 37°C (LRIG1). (Beta-catenin only): 
Apply Mouse Detective (mouse protein blocker) for 40 min at 37°C. Primary 
antibody is applied for 1 h at 37°C (VDAC1 at a 1:300 dilution). Primary 
antibody is applied for 1 h at room temperature (Ki-67 at a 1:600 dilution). 
Primary antibody is applied for 1 h at 37°C (CK20 at a 1:500 dilution). 
Primary antibody is applied for 1 h at 37°C (MPC1 at a 1:200 dilution). 
Primary antibody is applied for 1 h at 37°C (Beta-catenin at a 1:200 dilution). 
Primary antibody is applied for 1 h at room temperature (LRIG1 at a 1:700 
dilution). Apply the secondary antibody (rabbit anti-mouse Fab, Dako, 
catalog # E0413) at a dilution of 1:100 for 24 min at 37°C (Beta-catenin). 
Apply the secondary antibody (goat anti-rabbit IgG, Sigma, catalog #B8895) 
at a dilution of 1:100 for 32 min at 35°C (Ki-67 and LRIG1) or 40 min at 37°C 
(VDAC1 and CK20). Detection of slides was performed on the Ventana 
BenchMark™ Discovery automated system using the DAB Map detection kit 
which incorporates a peroxidase inhibitor (3% H2O2), a blocker to reduce 
background staining, a streptavidin horseradish peroxidase conjugate, 3-3, 




(Ventana Medical Systems). Counterstain slides with hematoxylin for 8 min 
(Ventana Medical Systems). Blue slides for 4 min (Ventana Medical 
Systems). Remove slides from the autostainer and placed in a mixture of 
DAWN/dH2O. Wash slides in the DAWN/dH2O to remove any oil applied by 
the autostainer. Rinse slides in dH2O. Place slides in Iodine to remove any 
precipitate from fixation. Place slides in Sodium Thiosulfate to clear Iodine. 
Rinse slides in dH2O. De-hydrate slides in graded alcohols (70% x1, 95% x2 
and 100% x2) 30 s each. Clear slides in 4 changes of xylene 10 dips each. 
Coverslip slides.   
The following antibodies were used for IHC analysis: Lrig1 (Abcam, 
ab36707, rabbit polyclonal antibody); CK20 (Abcam, ab118574, rabbit 
polyclonal antibody); VDAC1 (Abcam, ab34726, rabbit polyclonal antibody); 
Beta-catenin (BD Transduction Laboratories, 610154, clone 14); Ki-67  
(Abcam, ab15580, rabbit polyclonal antibody); MPC1 (Sigma, HPA045119, 
rabbit polyclonal antibody). 
 
4.5.4 Slide Imaging and Histology 
 Slides were imaged on an Axioscan Z.1 slide scanner (Carl Zeiss 
Optics) using the “Medium Size, Medium Stain” scan wizard profile for H&E 
sections and the “Medium Size, Faint Stain” scan wizard profile for IHC 
sections. Fine focus map was calculated using “onion skin” method at 0.5. 




Pro 2 (Carl Zeiss), and regions of interest were exported for further analysis 
by ImageJ. 
 
4.5.5 MEF Isolation 
 Heterozygous Mpc1flox mice were intercrossed to generate pups with 
the Mpc1 allelic series. Male and female mice were placed together for 3 days 
in harem breeding before removing the male. Observation of a vaginal plug 
was noted and female weights were monitored for the subsequent 9 days. 
Pregnant females were then sacrificed, and MEFs were generated following 
the Jacks lab protocol (http://web.mit.edu/jacks-
lab/protocols/Making_MEFs_tables.html). MEFs were maintained in 
Dulbecco’s modified Eagle’s medium +2mM Glutamax (Invitrogen) with 15% 
FBS (Sigma Aldrich) and 1% primocin at 37˚C in 5% CO2. 
 
4.5.6 Transfection/Microscopy/FACS 
MEFs were transfected using Lipofectamine 3000 (Invitrogen) and 
plasmids encoding either GFP54 or GFPCre39 (Addgene #11920). Cells were 
imaged on the Axio Observer Z1 imaging system (Carl Zeiss) equipped with 
10x, 40x, and 100x objectives (oil immersion). Digital fluorescence and 
differential interference contrast (DIC) images were acquired using a 
monochrome digital camera (AxioCam Mrm, Carl Zeiss). The final images 




and contrast were adjusted only using linear operations across the entire 
image.  
Cells were sorted 48h after transfection for GFP positive cells on BD 
FACSAria II after excitation with the 488nm laser and read with the 530/30 
optical filter set.  
 
4.5.7 Immunoblotting 
Samples were prepared, and immunoblotting conducted as described 
previously.37 Proprietary MPC1 and MPC2 antibodies were developed and 
tested in collaboration with Cell Signaling Technologies.  
 
4.5.8 Statistical Methods 
Statistical analyses were performed using Graphpad Prism 6. Unless 
otherwise noted, data were analyzed by Student’s t test and considered 
significant at p < 0.05. 
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 The discovery of the genes encoding the MPC has provided a new lens 
for us to view cancer metabolism. The work presented in this thesis provides 
answers to just a small portion of the questions that remain regarding the 
MPC and its role in normal and pathologic cellular metabolism.   
The regulation of the MPC, both transcriptionally and post-
translationally have yet to be determined and will play an important role in 
understanding how mitochondrial pyruvate metabolism is modulated in 
normal physiology.   Many biochemical questions remain unanswered, such 
as the molecular structure of the MPC complex, substrate cooperativity, and 
binding partners of the MPC, and the mechanism of MPC complex removal 
from the mitochondria when either MPC1 or MPC2 are absent. As pointed 
out in Chapter 2, the fate of pyruvate is highly regulated by enzymes and 
proteins other than the MPC, and determining which contexts the MPC 
becomes the rate limiting step in pyruvate metabolism (vs. a redundant 
blockade in its absence), will be essential to effective therapeutic exploitation 




Beyond the scope of the MPC, the field of cancer metabolism continues 
to rapidly grow. One of the most interesting, and challenging facets to the 
field will be understanding and modelling metabolic tumor heterogeneity. 
Currently no models exist to study tumor heterogeneity, nor does robust 
technology exist to assess metabolism at the single-cell level. As discussed in 
Chapter 2, this hurdle is essential to overcome if metabolic cancer therapies 
are to expand in their use beyond adjuvant chemotherapy. 
The study of stem cell metabolism is still a nascent field, and many of 
the mechanisms described in cancer metabolism may also play a role in stem 
cells. Our initial study on the effects of Mpc1 knockout in colon stem cells 
suggests that the MPC may play an important role in the maintenance of 
stemness, and/or the determination of cell fate. The question of whether 
forcing the Warburg Effect via Mpc1 knockout metabolically primes cells for 
transformation is an exciting prospect, and such a discovery would redefine 
our understanding of oncogenesis. 
 
